1 Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma[J]. Ann Neurol, 2007, 61(1): 25-36. PMID: 17262855. PMCID: PMC2430743. DOI: 10.1002/ana.21050.
2 Ren H, Fan S, Zhao Y, et al. The changing spectrum of antibody-mediated encephalitis in China[J]. J Neuroimmunol, 2021, 361: 577753. PMID: 34739913. DOI: 10.1016/j.jneuroim.2021.577753.
3 Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models[J]. Lancet Neurol, 2019, 18(11): 1045-1057. PMID: 31326280. DOI: 10.1016/S1474-4422(19)30244-3.
4 中华医学会神经病学分会. 中国自身免疫性脑炎诊治专家共识[J]. 中华神经科杂志, 2017, 50(2): 91-98. DOI: 10.3760/cma.j.issn.1006-7876.2017.02.004.
5 Zuliani L, Nosadini M, Gastaldi M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations[J]. Neurol Sci, 2019, 40(10): 2017-2030. PMID: 31161339. DOI: 10.1007/s10072-019-03930-3.
6 Nosadini M, Thomas T, Eyre M, et al. International consensus recommendations for the treatment of pediatric NMDAR antibody encephalitis[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(5): e1052. PMID: 34301820. PMCID: PMC8299516. DOI: 10.1212/NXI.0000000000001052.
7 Li X, Hou C, Wu WL, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis in southern China: analysis of 111 cases[J]. J Neuroimmunol, 2021, 352: 577479. PMID: 33486307. DOI: 10.1016/j.jneuroim.2021.577479.
8 Seifert-Held T, Eberhard K, Lechner C, et al. Functional recovery in autoimmune encephalitis: a prospective observational study[J]. Front Immunol, 2021, 12: 641106. PMID: 34093529. PMCID: PMC8175889. DOI: 10.3389/fimmu.2021.641106.
9 Zhang Y, Liu G, Jiang M, et al. Efficacy of therapeutic plasma exchange in patients with severe refractory anti-NMDA receptor encephalitis[J]. Neurotherapeutics, 2019, 16(3): 828-837. PMID: 30868469. PMCID: PMC6694354. DOI: 10.1007/s13311-019-00725-4.
10 Guang S, Ma J, Ren X, et al. Immunotherapies for anti-N-M-methyl-D-aspartate receptor encephalitis: multicenter retrospective pediatric cohort study in China[J]. Front Pediatr, 2021, 9: 691599. PMID: 34268281. PMCID: PMC8276978. DOI: 10.3389/fped.2021.691599.
11 Buttgereit F. Glucocorticoids: surprising new findings on their mechanisms of actions[J]. Ann Rheum Dis, 2021, 80(2): 137-139. PMID: 33162396. DOI: 10.1136/annrheumdis-2020-218798.
12 王国丽, 尹飞, 王颖, 等. 儿童抗N-甲基-D-天门冬氨酸受体脑炎71例临床分析[J]. 中华儿科杂志, 2019, 57(2): 125-130. PMID: 30695887. DOI: 10.3760/cma.j.issn.0578-1310.2019.02.012.
13 Zhang Y, Huang HJ, Chen WB, et al. Clinical efficacy of plasma exchange in patients with autoimmune encephalitis[J]. Ann Clin Transl Neurol, 2021, 8(4): 763-773. PMID: 33609012. PMCID: PMC8045938. DOI: 10.1002/acn3.51313.
14 Jamshidian A, Abd-Nikfarjam B, Khademi Z, et al. Therapeutic plasma exchange may adjust IL-6 and TGF-β signals in relapsed MS patients peripheral blood[J]. J Clin Apher, 2020, 35(2): 72-78. PMID: 31899560. DOI: 10.1002/jca.21755.
15 Zanatta E, Cozzi M, Marson P, et al. The role of plasma exchange in the management of autoimmune disorders[J]. Br J Haematol, 2019, 186(2): 207-219. PMID: 30924130. DOI: 10.1111/bjh.15903.
16 Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue[J]. J Clin Apher, 2019, 34(3): 171-354. PMID: 31180581. DOI: 10.1002/jca.21705.
17 Chen Y, Wang C, Xu F, et al. Efficacy and tolerability of intravenous immunoglobulin and subcutaneous immunoglobulin in neurologic diseases[J]. Clin Ther, 2019, 41(10): 2112-2136. PMID: 31445679. DOI: 10.1016/j.clinthera.2019.07.009.
18 Yang S, Yang L, Liao H, et al. Clinical characteristics and prognostic factors of children with anti-N-methyl-D-aspartate receptor encephalitis[J]. Front Pediatr, 2021, 9: 605042. PMID: 33968840. PMCID: PMC8100243. DOI: 10.3389/fped.2021.605042.
19 Raja P, Shamick B, Nitish LK, et al. Clinical characteristics, treatment and long-term prognosis in patients with anti-NMDAR encephalitis[J]. Neurol Sci, 2021, 42(11): 4683-4696. PMID: 33728548. DOI: 10.1007/s10072-021-05174-6.
20 Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[J]. Lancet Neurol, 2013, 12(2): 157-165. PMID: 23290630. PMCID: PMC3563251. DOI: 10.1016/S1474-4422(12)70310-1.
21 Wang K, Chen Z, Wu D, et al. Early second-line therapy is associated with improved episodic memory in anti-NMDA receptor encephalitis[J]. Ann Clin Transl Neurol, 2019, 6(7): 1202-1213. PMID: 31353868. PMCID: PMC6649545. DOI: 10.1002/acn3.50798.
22 Xu X, Lu Q, Huang Y, et al. Anti-NMDAR encephalitis: a single-center, longitudinal study in China[J]. Neurol Neuroimmunol Neuroinflamm, 2020, 7(1): e633. PMID: 31619447. PMCID: PMC6857906. DOI: 10.1212/NXI.0000000000000633.
23 Shim Y, Kim SY, Kim H, et al. Clinical outcomes of pediatric anti-NMDA receptor encephalitis[J]. Eur J Paediatr Neurol, 2020, 29: 87-91. PMID: 33046392. DOI: 10.1016/j.ejpn.2020.10.001.
24 Zhang XT, Wang CJ, Wang BJ, et al. The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory anti-N-methyl-D-aspartate receptor encephalitis: two case reports[J]. CNS Neurosci Ther, 2019, 25(1): 151-153. PMID: 30345626. PMCID: PMC6436585. DOI: 10.1111/cns.13078.
25 Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management[J]. J Neurol Neurosurg Psychiatry, 2021, 92(7): 757-768. PMID: 33649022. PMCID: PMC8223680. DOI: 10.1136/jnnp-2020-325300.
26 Mooneyham GC, Ferrafiat V, Stolte E, et al. Developing consensus in the assessment and treatment pathways for autoimmune encephalitis in child and adolescent psychiatry[J]. Front Psychiatry, 2021, 12: 638901. PMID: 33854451. PMCID: PMC8039450. DOI: 10.3389/fpsyt.2021.638901.
27 Dou X, Li D, Wu Y, et al. Efficacy and safety of rituximab in Chinese children with refractory anti-NMDAR encephalitis[J]. Front Neurol, 2020, 11: 606923. PMID: 33381080. PMCID: PMC7767921. DOI: 10.3389/fneur.2020.606923.
28 Bartolini L, Muscal E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey[J]. J Neurol, 2017, 264(4): 647-653. PMID: 28154970. DOI: 10.1007/s00415-017-8407-1.
29 Cao XS, Kessi M, Ji TY, et al. A survey on pediatric anti-N-methyl-D-aspartate-receptor encephalitis treatment strategies in China[J]. Chin Med J (Engl), 2020, 134(12): 1498-1499. PMID: 33323814. PMCID: PMC8213264. DOI: 10.1097/CM9.0000000000001308.
30 Nepal G, Shing YK, Yadav JK, et al. Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis[J]. Acta Neurol Scand, 2020, 142(5): 449-459. PMID: 32484900. DOI: 10.1111/ane.13291.
31 Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort[J]. Neurology, 2016, 86(18): 1683-1691. PMID: 27037228. DOI: 10.1212/WNL.0000000000002635.
32 Deng B, Yu H, Liu X, et al. Reduced dosage rituximab in the treatment of anti-N-methyl-D-aspartate receptor encephalitis: an observation study in Chinese patients[J]. J Neuroimmunol, 2019, 330: 81-86. PMID: 30851542. DOI: 10.1016/j.jneuroim.2019.02.008.
33 Wang BJ, Wang CJ, Zeng ZL, et al. Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour[J]. J Neurol Sci, 2017, 377: 127-132. PMID: 28477682. DOI: 10.1016/j.jns.2017.04.007.
34 Zou X, Zhao W, Kong M, et al. Low-dose rituximab in the treatment of anti-N-methyl-D-aspartate receptor encephalitis with antibody superposition syndrome: a case report[J]. Acta Neurol Belg, 2022, 22(3): 797-799. PMID: 33689111. DOI: 10.1007/s13760-021-01636-y.
35 Dhawan SR, Sankhyan N. Low-dose rituximab in children with anti-NMDAR encephalitis[J]. Pediatr Neurol, 2018, 87: 82. PMID: 30501890. DOI: 10.1016/j.pediatrneurol.2018.07.006.
36 Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy[J]. Cancer Chemother Pharmacol, 2016, 78(4): 661-671. PMID: 27646791. DOI: 10.1007/s00280-016-3152-1.
37 Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies[J]. Neurotherapeutics, 2016, 13(1): 147-162. PMID: 26692392. PMCID: PMC4720680. DOI: 10.1007/s13311-015-0410-6.
38 林希, 陈丽婷, 曾甲斌, 等. 环磷酰胺对一线免疫治疗失败的儿童抗N-甲基-D-天冬氨酸受体脑炎疗效分析[J]. 中国神经精神疾病杂志, 2020, 46(2): 98-102. DOI: 10.3969/j.issn.1002-0152.2020.02.008.
39 Casares M, Skinner HJ, Gireesh ED, et al. Successful intrathecal rituximab administration in refractory nonteratoma anti-N-methyl-D-aspartate receptor encephalitis: a case report[J]. J Neurosci Nurs, 2019, 51(4): 194-197. PMID: 31180943. DOI: 10.1097/JNN.0000000000000450.
40 Santiago JA, Babico M, Stitt G, et al. Low-dose intrathecal rituximab is a safe and potentially effective treatment for pediatric neuroimmunologic disorders[J]. J Neuroimmunol, 2021, 359: 577687. PMID: 34364103. DOI: 10.1016/j.jneuroim.2021.577687.
41 Yang XZ, Zhu HD, Ren HT, et al. Utility and safety of intrathecal methotrexate treatment in severe anti-N-methyl-D-aspartate receptor encephalitis: a pilot study[J]. Chin Med J (Engl), 2018, 131(2): 156-160. PMID: 29336363. PMCID: PMC5776845. DOI: 10.4103/0366-6999.222327.
42 Eaton JE, Kleinholz-Owens P, Sriram S, et al. Intrathecal methotrexate—another tool for the treatment of refractory autoimmune encephalitis—single institution cohort and literature review[J]. J Neurol Sci, 2021, 431: 120042. PMID: 34740019. DOI: 10.1016/j.jns.2021.120042.
43 Wang T, Wang B, Zeng Z, et al. Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study[J]. J Neuroimmunol, 2021, 354: 577527. PMID: 33652303. DOI: 10.1016/j.jneuroim.2021.577527.
44 Dinoto A, Cheli M, Bratina A, et al. Bortezomib in anti-N-methyl-D-aspartate-receptor (NMDA-R) encephalitis: a systematic review[J]. J Neuroimmunol, 2021, 356: 577586. PMID: 33975246. DOI: 10.1016/j.jneuroim.2021.577586.
45 Lim JA, Lee ST, Moon J, et al. New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2[J]. J Neuroimmunol, 2016, 299: 107-111. PMID: 27725107. DOI: 10.1016/j.jneuroim.2016.09.001.
46 Govil-Dalela T, Datta I, Williams M. Refractory NMDA-receptor encephalitis in a teenager: a novel use of Bortezomib[J]. J Neuroimmunol, 2021, 355: 577565. PMID: 33813318. DOI: 10.1016/j.jneuroim.2021.577565.
47 Cordani R, Micalizzi C, Giacomini T, et al. Bortezomib-responsive refractory anti-N-methyl-D-aspartate receptor encephalitis[J]. Pediatr Neurol, 2020, 103: 61-64. PMID: 31759783. DOI: 10.1016/j.pediatrneurol.2019.09.004.
48 Shin YW, Lee ST, Kim TJ, et al. Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis[J]. Ann Clin Transl Neurol, 2018, 5(5): 598-605. PMID: 29761122. PMCID: PMC5945964. DOI: 10.1002/acn3.557.
49 Wickel J, Chung HY, Platzer S, et al. Generate-boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis[J]. Trials, 2020, 21(1): 625. PMID: 32641101. PMCID: PMC7346383. DOI: 10.1186/s13063-020-04516-7.
50 Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family[J]. Int Immunopharmacol, 2005, 5(12): 1731-1740. PMID: 16102523. DOI: 10.1016/j.intimp.2005.05.010.
51 Lee WJ, Lee ST, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study[J]. Neurotherapeutics, 2016, 13(4): 824-832. PMID: 27215218. PMCID: PMC5081109. DOI: 10.1007/s13311-016-0442-6.
52 Ratuszny D, Skripuletz T, Wegner F, et al. Case report: daratumumab in a patient with severe refractory anti-NMDA receptor encephalitis[J]. Front Neurol, 2020, 11: 602102. PMID: 33414761. PMCID: PMC7782967. DOI: 10.3389/fneur.2020.602102.
53 Lazzarin SM, Vabanesi M, Cecchetti G, et al. Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review[J]. J Neurol, 2020, 267(8): 2462-2468. PMID: 32535682. DOI: 10.1007/s00415-020-09988-w.
54 Yang J, Liu X. Immunotherapy for refractory autoimmune encephalitis[J]. Front Immunol, 2021, 12: 790962. PMID: 34975890. PMCID: PMC8716621. DOI: 10.3389/fimmu.2021.790962.
55 Nosadini M, Mohammad SS, Toldo I, et al. Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: a systematic literature review[J]. Eur J Paediatr Neurol, 2019, 23(1): 7-18. PMID: 30318435. DOI: 10.1016/j.ejpn.2018.09.008.
56 Downing HJ, Pirmohamed M, Beresford MW, et al. Paediatric use of mycophenolate mofetil[J]. Br J Clin Pharmacol, 2013, 75(1): 45-59. PMID: 22519685. PMCID: PMC3555046. DOI: 10.1111/j.1365-2125.2012.04305.x.